Maxim Group Reiterates Buy Rating on OXBR
Analyst Allen Klee maintains a buy rating with a $3.00 target for OXBR, a 183.02% upside from the current price.
Key Points
- Maxim Group analyst Allen Klee reiterated a buy rating on OXBR with a $3.00 price target on June 17, 2026.
- Maxim Group's $3 price target implies 183.02% upside from Oxbridge Re Holdings Limited's ($OXBR) current $1.06 share price.
- Shares of OXBR are trading at $1.06, reflecting recent market activity and institutional adjustments.
- Insider Martin Allan sold shares multiple times, while institutional investors like Geode Capital and Vanguard Capital adjusted their holdings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Maxim Group analyst Allen Klee reiterated his buy rating on OXBR on June 17, 2026, setting a price target of $3.00. The stock, which is currently trading at $1.06, has seen various institutional and insider activities that may interest investors.
Other Institutional Activity in OXBR
Geode Capital Management increased its holdings in OXBR by 10,607 shares, bringing its total to 166,043 shares valued at approximately $195,929. LPL Financial LLC maintained its position with 100,673 shares worth around $118,794. Henrickson Nauta Wealth Advisors, however, reduced its stake by 69,620 shares, now holding 67,780 shares valued at $79,980. Vanguard Capital Management started a new position with 58,483 shares valued at about $69,010. Meanwhile, International Assets Investment Management boosted its holdings by 18,227 shares to 48,000, valued at $53,760. Renaissance Technologies trimmed its position by 11,609 shares, ending with 32,700 shares worth $38,586.
Insider Buying and Selling at Oxbridge Re Holdings Limited
Insider Martin Allan has been actively selling shares of OXBR. On April 16, 2026, Allan sold 135,134 shares at an average price of $0.72. Additionally, he sold 4,328 shares at $2.45 on September 16, 2025, and another 10,000 shares at $2.39 on August 27, 2025. Earlier, on July 24, 2025, Allan sold 2,000 shares at an average price of $2.43.
Analysts Set New Price Targets
On June 17, 2026, Maxim Group maintained its buy rating on OXBR with a price target of $3.00. This follows an earlier initiation of coverage with a buy rating and a $5.00 target on April 30, 2025. The consensus recommendation for OXBR remains positive, with analysts expecting the stock to reach the target price based on fundamentals.
About OXBR
OXBR operates in the financial sector, focusing on providing reinsurance services. The company is involved in underwriting insurance and reinsurance policies, serving various markets. Despite its niche focus, OXBR continues to attract attention from both analysts and institutional investors.
Bottom Line
Maxim Group's reiteration of a buy rating with a $3.00 target underscores ongoing interest in OXBR. The stock's current trading price of $1.06, coupled with significant insider sales and varied institutional activity, provides a dynamic backdrop for potential investors. As always, it's important to remember that analyst ratings and 13F filings reflect past positions and may not indicate current investment strategies.
Get Oxbridge Re Holdings Limited alerts
New 13F filings, insider trades, and analyst moves on $OXBR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.